Partner Headlines - BMRN

  1. 2 DMD drugs make progress

    IBD
  2. BioMarin, Sarepta Muscular Dystrophy Drugs Progress

    IBD
  3. Baird Downgrades BioMarin Pharmaceutical To Neutral

    Benzinga
  4. Benzinga's Volume Movers

    Benzinga
  5. Benzinga's Top Downgrades

    Benzinga
  6. Mid-Afternoon Market Update: BioMarin Pharmaceutical Jumps Following ...

    Benzinga
  7. Mid-Day Market Update: Oracle Drops On Downbeat Results; Radius ...

    Benzinga
  8. BioMarin Stock Hits High On Dwarfism Drug Success

    IBD
  9. Mid-Morning Market Update: Markets Open Higher; Kroger Earnings ...

    Benzinga
  10. Benzinga's Volume Movers

    Benzinga
  11. Morning Market Gainers

    Benzinga
  12. Dollar, Data Boost Stock Futures; Oracle Tumbles, Taser Gains

    IBD
  13. Benzinga's Top #PreMarket Gainers

    Benzinga
  14. BIOMARIN PHARMA

    IBD
  15. Pier 1, BioMarin, HomeAway & Oracle Lead Wednesday's After-Hours ...

    Benzinga
  16. BMN 111 (vosoritide) Improves Growth Velocity in Children With ...

    Benzinga
  17. BioMarin Submits Drisapersen MAA to EMA for the Treatment of ...

    Benzinga
  18. Benzinga's Top Initiations

    Benzinga
  19. Barclays Initiates BioMarin Pharmaceutical With Overweight

    Benzinga
  20. Sarepta Soars On New Hope For Muscular-Dystrophy Drug

    IBD
  21. Alexion's $8.4 Billion Synageva Buyout Spooks Street

    IBD
  22. BIOMARIN PHARMA

    IBD
  23. BioMarin Completes Rolling NDA Submission to FDA for Drisapersen ...

    Benzinga
  24. J.P. Morgan's 3 Biotechnology Picks

    GuruFocus
  25. What Evercore Is Watching At BioMarin Pharmaceutical

    Benzinga
  26. BioMarin To Report Revenue In-line With Consensus, Wedbush Says

    Benzinga
  27. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD
  28. Bank Of America Upgrades Sarepta Therapeutics On 'Increased Conviction' ...

    Benzinga
  29. Regeneron Q4 Sales, 2015 Outlook Upbeat On Eylea

    IBD
  30. BIOMARIN PHARMA

    IBD
  31. State Of The Union Lights Up Biotech

    Benzinga
  32. Nomura Analyst Sees Fast Growth At BioMarin Pharmaceutical

    Benzinga
  33. UPDATE: Nomura Raises Price Target On BioMarin Pharmaceutical ...

    Benzinga
  34. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  35. Regeneron Jumps On Favorable Cholesterol Drug Report

    IBD
  36. 5 Potential Blockbuster Drugs Set To Launch In 2015

    IBD
  37. What Investors Are Looking For In NPS Pharmaceuticals Ahead Of ...

    Benzinga
  38. BioMarin CEO Sees Big Future For Prosensa Drug

    IBD
  39. UPDATE: UBS Securities Reiterates On BioMarin Pharmaceutical ...

    Benzinga
  40. FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion ...

    Benzinga
  41. BioMarin Will Report Breadth of Innovative Development Pipeline ...

    Benzinga
  42. Benzinga's M&A Chatter for Monday November 24, 2014

    Benzinga
  43. BioMarin buying Prosensa

    IBD
  44. Trio Of Major Deals Disclosed

    IBD
  45. Mid-Afternoon Market Update: Trina Solar Drops After Quarterly ...

    Benzinga
  46. Mid-Day Market Update: Dow Edges Lower; Platinum Underwriters ...

    Benzinga
  47. Mid-Morning Market Update: Markets Open Higher; BioMarin To Acquire ...

    Benzinga
  48. Benzinga's Volume Movers

    Benzinga
  49. BioMarin Buying Prosensa, Backing Up Troubled Drug

    IBD
  50. Stocks Hitting 52-Week Highs

    Benzinga
  51. Morning Market Movers

    Benzinga
  52. Stock Futures Trending Higher; Kate Spade Bags An Upgrade

    IBD
  53. BioMarin Pharmaceuticals To Acquire Prosensa

    Benzinga
  54. Benzinga's Top #PreMarket Gainers

    Benzinga
  55. US Stock Futures Up Ahead Of Economic Data

    Benzinga
  56. Stocks Hitting 52-Week Highs

    Benzinga
  57. Benzinga's Top Upgrades

    Benzinga
  58. Benzinga's M&A Chatter for Tuesday October 21, 2014

    Benzinga
  59. BioMarin Weathers The Storm

    Benzinga
  60. 4 Top-Rated Drugmakers Beat Q2 Earnings Estimates

    IBD
  61. Biogen Hemophilia Drugs Launch Into The Unknown

    IBD
  62. UPDATE: Credit Suisse Upgrades BioMarin Pharmaceutical

    Benzinga
  63. Benzinga's Top Upgrades

    Benzinga
  64. BioMarin, Medivation Buck Biotech Short Interest Trend (BIIB, ...

    Benzinga
  65. Amgen, BioMarin Lead Biotech Short Interest Trend (AMGN, BIIB, ...

    Benzinga
  66. Top Trending Tickers On StockTwits For February 18

    Benzinga
  67. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga
  68. You Can No Longer Ignore Biotech

    GuruFocus
  69. New Year Short Interest Swings In Biotech (BIIB, BMRN, MDVN)

    Benzinga
  70. Celgene, Dendreon Lead Short Interest Trend In Biotechs (BMRN, ...

    Benzinga
  71. UPDATE: Piper Jaffray Initiates Coverage on BioMarin Pharmaceutical ...

    Benzinga
  72. UPDATE: Piper Jaffray Initiates On BioMarin Pharmaceuticals On ...

    Benzinga
  73. BioMarin Wins FDA Panel Vote, Cuts Deal With Myriad

    IBD
  74. Benzinga's Top #PreMarket Gainers

    Benzinga
  75. BioMarin Confirms FDA Panel Recommends Approval of Vimizim for ...

    Benzinga
  76. BioMarin Stock Trading Halted Today for FDA Endocrinologic and ...

    Benzinga
  77. Gilead Sciences Leads In Rising Short Interest Among Biotechs ...

    Benzinga
  78. Catalyst Stock Plunge: Ugly In Orphan Drug Land

    YCharts
  79. BioMarin Initiates Phase 3 BMN 673 Trial for Metastatic gBRCA ...

    Benzinga
  80. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics ...

    Benzinga
  81. US Oncology, Biomarin Announce Collaboration to Launch PARP Inhibitor ...

    Benzinga
  82. Roche

    IBD
  83. BioMarin Announces 5 Poster Presentations on BMN 673 at AACR-NCI-EORTC ...

    Benzinga
  84. Short Sellers Move On Amgen, Vertex (AMGN, PCYC, VRTX)

    Benzinga
  85. Orphan Drugs: No (Payer) News Is Good News

    YCharts
  86. BioMarin Presents Positive Phase 1/2 Data on BMN 673 in Breast ...

    Benzinga
  87. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, ...

    Benzinga
  88. Market Primer: Friday, September 20: US Markets Fall As Investors ...

    Benzinga
  89. Benzinga's M&A Chatter for Thursday September 19, 2013

    Benzinga
  90. Report: Roche Lines up $15B in Debt to Buy BioMarin

    FoxBusiness
  91. Benzinga's Volume Movers

    Benzinga
  92. Benzinga's Top Pre-Market Gainers

    Benzinga
  93. UPDATE: Stifel Downgrades BioMarin Pharmaceutical on Appropriate ...

    Benzinga
  94. Benzinga's Top Pre-Market Gainers

    Benzinga
  95. Alexion, Pharmacyclics Buck Trend in Biotech Short Interest (ALXN, ...

    Benzinga
  96. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  97. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  98. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
  99. UPDATE: Stifel Nicolaus Upgrades BioMarin Pharmaceutical on Catalysts

    Benzinga
  100. Biomarin Pharmaceutical, Inc. (BMRN) CEO Jean Jacques Bienaime ...

    GuruFocus
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!